Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$4.70 -2.9%	$4.39	$2.94 ▼ $10.25	$269.79M	3.05	142,719 shs	127,545 shs
PROK ProKidney	$0.59 -11.5%	$0.80	$0.46 ▼ $2.59	$195.73M	1.36	696,191 shs	1.61 million shs
RPTX Repare Therapeutics	$1.39	$1.39	$0.89 ▼ $4.29	$59.62M	0.84	247,426 shs	58,069 shs
RZLT Rezolute	$4.46 +2.5%	$4.01	$2.22 ▼ $6.19	$372.01M	1.04	636,057 shs	2.22 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	0.00%	+2.54%	+16.91%	+32.60%	-15.83%
PROK ProKidney	0.00%	+1.30%	-5.60%	-23.68%	-72.82%
RPTX Repare Therapeutics	0.00%	-1.42%	0.00%	+40.99%	-57.88%
RZLT Rezolute	0.00%	+5.84%	+6.36%	+50.00%	+1.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FHTX Foghorn Therapeutics	2.1153 of 5 stars	3.6	0.0	3.2	1.7	0.6
PROK ProKidney	2.0789 of 5 stars	3.0	0.0	2.3	4.2	0.6
RPTX Repare Therapeutics	2.6858 of 5 stars	3.3	3.0	2.2	2.5	0.6
RZLT Rezolute	3.0995 of 5 stars	3.6	1.0	4.2	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	157.98% Upside
PROK ProKidney	2.00	Hold	$3.50	491.12% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	223.74% Upside
RZLT Rezolute	3.14	Buy	$11.83	165.32% Upside

Current Analyst Ratings Breakdown

Latest RPTX, PROK, FHTX, and RZLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	RZLT Rezolute	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/28/2025	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
4/23/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$22.60M	11.59	N/A	N/A	($0.82) per share	-5.73
PROK ProKidney	$80K	2,166.35	N/A	N/A	($3.41) per share	-0.17
RPTX Repare Therapeutics	$53.48M	1.11	N/A	N/A	$3.56 per share	0.39
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$3.01	N/A	N/A	N/A	N/A	-78.12%	-67.11%	N/A
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)

Latest RPTX, PROK, FHTX, and RZLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/13/2025	Q3 2025	RZLT Rezolute	-$0.22	-$0.27	-$0.05	-$0.27	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.16	3.16
PROK ProKidney	N/A	10.96	10.96
RPTX Repare Therapeutics	N/A	7.42	7.42
RZLT Rezolute	N/A	8.43	8.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
PROK ProKidney	51.59%
RPTX Repare Therapeutics	85.09%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	7.58%
PROK ProKidney	41.49%
RPTX Repare Therapeutics	11.50%
RZLT Rezolute	18.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable
RPTX Repare Therapeutics	180	42.89 million	37.96 million	Optionable
RZLT Rezolute	40	85.52 million	69.79 million	Optionable

RPTX, PROK, FHTX, and RZLT Headlines

Recent News About These Companies

Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 27 at 7:49 AM | insidertrades.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Insider Buys 2,500 Shares of Stock

June 26, 2025 | marketbeat.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Acquires 1,230,769 Shares of Stock

June 26, 2025 | americanbankingnews.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

June 25, 2025 | insidertrades.com

Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $20,250.00 in Stock

June 24, 2025 | marketbeat.com

Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 24, 2025 | insidertrades.com

Young-Jin Kim Acquires 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 23, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Buy" from Analysts

June 14, 2025 | marketbeat.com

Bank of America Corp DE Has $443,000 Stock Position in Rezolute, Inc. (NASDAQ:RZLT)

June 12, 2025 | marketbeat.com

69,724 Shares in Rezolute, Inc. (NASDAQ:RZLT) Bought by Ameriprise Financial Inc.

June 6, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%

June 3, 2025 | finance.yahoo.com

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025 | globenewswire.com

Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 21, 2025 | finanznachrichten.de

Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential

May 20, 2025 | finance.yahoo.com

Rezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia Treatment

May 15, 2025 | nasdaq.com

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025 | globenewswire.com

FDA grants breakthrough status to Rezolute’s hypoglycemia therapy

May 6, 2025 | investing.com

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025 | globenewswire.com

Rezolute to Participate in Upcoming Investor Conferences

May 1, 2025 | globenewswire.com

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025 | seekingalpha.com

Rezolute Closes $96.9 Million Underwritten Offering

April 28, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, PROK, FHTX, and RZLT Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$4.70 -0.14 (-2.89%)

As of 04:00 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ProKidney NASDAQ:PROK

$0.59 -0.08 (-11.46%)

As of 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Repare Therapeutics NASDAQ:RPTX

$1.39 0.00 (0.00%)

As of 04:00 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Rezolute NASDAQ:RZLT

$4.46 +0.11 (+2.53%)

As of 04:00 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time